Olema Pharmaceuticals, Inc.于2006年8月7日在特拉华州注册成立。该公司是一家临床阶段的生物制药公司，专注于为乳腺癌开发下一代靶向疗法。其主要候选药物palazestrant是一种口服小分子，具有雌激素受体拮抗剂和降解剂的双重活性，目前正在针对ER+/HER2-转移性乳腺癌进行3期试验。
董事
名称
职位
Sean Bohen
President,Principal Financial Officer,Chief Executive Officer and Director
イアンクラーク
Chairperson of the Board
Andrew Rappaport
Director
Cynthia Butitta
Director
Cyrus L. Harmon
Director
Gorjan Hrustanovic
Director
Graham Walmsley
Director
Sandra Horning
Director
Scott Garland
Director
Yi Larson
Director
股东
名称
职位
Sean Bohen
President,Principal Financial Officer,Chief Executive Officer and Director
David C. Myles
Chief Discovery and Non-Clinical Development Officer